Catalent Inc (NASDAQ:CTLT) will post its quarterly earnings results after the market closes on Monday, November 6th. Analysts expect Catalent to post earnings of $0.20 per share for the quarter.
Catalent (NASDAQ:CTLT) last posted its earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The company had revenue of $616.90 million for the quarter, compared to the consensus estimate of $547.48 million. During the same quarter in the prior year, the company earned $0.52 earnings per share. Catalent’s revenue was up 15.9% on a year-over-year basis.
Catalent Inc (CTLT) opened at $42.70 on Friday. Catalent Inc has a 1-year low of $21.85 and a 1-year high of $43.39.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
A number of research analysts have weighed in on the company. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a report on Friday. Needham & Company LLC reissued a “hold” rating on shares of Catalent in a report on Monday, October 23rd. BidaskClub upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Morgan Stanley upgraded Catalent from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $29.00 to $48.00 in a research report on Thursday, September 21st. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $41.67.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
What are top analysts saying about Catalent Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent Inc and related companies.